Both AstraZeneca and Novartis announced that drugs they had for depression and hypertension that were in the late stages of development have failed, reports Bloomberg, adding that AstraZeneca's drugs turned out to be disappointing while Novartis's tests on Tekturna were halted due to safety concerns. Further, Sanofi's multiple sclerosis drug, Aubagio, has not performed better than an older therapy.